Sasa Vasilijic

Sasa Vasilijic

Auto-generated profile, based on publicly available information

Sasa Vasilijic

Eaton-Peabody Laboratories, Department of Otolaryngology, Massachusetts Eye and Ear, Boston, MA, 02114, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in Environmental Pollution
Verified
Journal Article
Closed access
SNSandra Nikolic
Sandra Nikolic
MJMarina Gazdic Jankovic
Marina Gazdic Jankovic
GRGvozden Rosic
Gvozden Rosic
MMMarina Miletic-Kovacevic
Marina Miletic-Kovacevic
NJNemanja Jovicic
Nemanja Jovicic
BLBiljana Ljujic
Biljana Ljujic

14 July 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LWLimeng Wu
Limeng Wu
SVSasa Vasilijic
Sasa Vasilijic
YSYao Sun
Yao Sun
JCJie Chen
Jie Chen
LLLukas D. Landegger
Lukas D. Landegger
LXLei Xu
Lei Xu
Normalizing the tumor microenvironment with losartan prevents tumor-induced hearing loss and enhances radiation response in schwannoma rodent models.

10 November 2023 in Science Advances
Verified
Journal Article
Closed access
SVSasa Vasilijic
Sasa Vasilijic
NANadia A. Atai
Nadia A. Atai
HHHiroshi Hyakusoku
Hiroshi Hyakusoku
SWSteven Worthington
Steven Worthington
YRYin Ren
Yin Ren
KSKonstantina Stankovic
Konstantina Stankovic
Vestibular schwannoma (VS) is an intracranial tumor arising from neoplastic Schwann cells and typically presenting with hearing loss. The traditional belief that hearing deficit is caused by physical expansion of the VS, compressing the auditory nerve, does not explain the common clinical finding that patients with small tumors can have profound hearing loss, suggesting that tumor-secreted factors could influence hearing ability in VS patients. We conducted profiling of patients’ plasma for 66 immune-related factors in patients with sporadic VS ( N > 170) and identified and validated candidate biomarkers associated with tumor size (S100B) and hearing (MCP-3). We further identified a nine-biomarker panel (TNR-R2, MIF, CD30, MCP-3, IL-2R, BLC, TWEAK, eotaxin, and S100B) with outstanding discriminatory ability for VS. These findings revealed possible therapeutic targets for VS, providing a unique diagnostic tool that may predict hearing change and tumor growth in VS patients, and may inform the timing of tumor resection to preserve hearing.

3 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JSJessica E. Sagers
Jessica E. Sagers
ABAdam S. Brown
Adam S. Brown
SVSasa Vasilijic
Sasa Vasilijic
RLRebecca M. Lewis
Rebecca M. Lewis
MSMehmet I. Sahin
Mehmet I. Sahin
KSKonstantina Stankovic
Konstantina Stankovic
The computational repositioning of existing drugs represents an appealing avenue for identifying effective compounds to treat diseases with no FDA-approved pharmacotherapies. Here we present the largest meta-analysis to date of differential gene expression in human vestibular schwannoma (VS), a debilitating intracranial tumor, and use these data to inform the first application of algorithm-based drug repositioning for this tumor class. We apply an open-source computational drug repositioning platform to gene expression data from 80 patient tumors and identify eight promising FDA-approved drugs with potential for repurposing in VS. Of these eight, mifepristone, a progesterone and glucocorticoid receptor antagonist, consistently and adversely affects the morphology, metabolic activity, and proliferation of primary human VS cells and HEI-193 human schwannoma cells. Mifepristone treatment reduces VS cell viability more significantly than cells derived from patient meningiomas, while healthy human Schwann cells remain unaffected. Our data recommend a Phase II clinical trial of mifepristone in VS.

1 March 2017 in Journal of Endodontics
Verified
Journal Article
Closed access
BCBojana Cetenovic
Bojana Cetenovic
BPBogomir Prokic
Bogomir Prokic
SVSasa Vasilijic
Sasa Vasilijic
BDBiljana Dojcinovic
Biljana Dojcinovic
MMMarko Magic
Marko Magic
DMDejan Markovic
Dejan Markovic

1 December 2015 in Cytotherapy
Verified
Journal Article
Closed access
BPBojan Pavlović
Bojan Pavlović
STSergej Tomic
Sergej Tomic
JĐJelena Đokić
Jelena Đokić
SVSaša Vasilijić
Saša Vasilijić
DVDragana Vučević
Dragana Vučević
MČMiodrag J Čolić
Miodrag J Čolić